Erle Mast - Clovis Oncology Co-Founder, CFO, Executive VP and Secretary
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Founder
Mr. Erle T. Mast is no longer Chief Financial Officer Executive Vice President of Clovis Oncology Inc. effective March 31 2016. He is one of the cofounders. Previously Mr. Mast served in the same role at Pharmion Corporation beginning in 2002. From 1997 through 2002 Mr. Mast worked for Dura Pharmaceuticals Inc. and its successor Elan Corporationrationration. From 2000 to 2002 he served as Chief Financial Officer for the Global Biopharmaceuticals business unit for Elan. From 1997 to 2000 Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. Prior to that Mr. Mast was a partner with Deloitte Touche LLP. Mr. Mast also serves on the board of directors of Zogenix Inc. and Receptos Inc. since 2009.
| Age | 51 |
| Tenure | 15 years |
| Phone | 303 625 5000 |
| Web | https://www.clovisoncology.com |
Clovis Oncology Management Efficiency
The company has return on total asset (ROA) of (0.3018) % which means that it has lost $0.3018 on every $100 spent on assets. This is way below average. Clovis Oncology's management efficiency ratios could be used to measure how well Clovis Oncology manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 436.77 M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has a current ratio of 1.15, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist Clovis Oncology until it has trouble settling it off, either with new capital or with free cash flow. So, Clovis Oncology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Clovis Oncology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Clovis to invest in growth at high rates of return. When we think about Clovis Oncology's use of debt, we should always consider it together with cash and equity.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people. Clovis Oncology (CLVS) is traded on NASDAQ Exchange in USA and employs 413 people. Management Performance
| Return On Asset | -0.3 |
Clovis Oncology Leadership Team
Elected by the shareholders, the Clovis Oncology's board of directors comprises two types of representatives: Clovis Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clovis. The board's role is to monitor Clovis Oncology's management team and ensure that shareholders' interests are well served. Clovis Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clovis Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Sussman, VP Relations | ||
| Thorlef Spickschen, Independent Director | ||
| BSc BSc, Exec Officer | ||
| Brian Atwood, Independent Director | ||
| Paul Klingenstein, Independent Director | ||
| Paul Gross, Executive Vice President Chief Compliance Officer, General Counsel | ||
| Robert Azelby, Director | ||
| Dale Hooks, Senior Vice President Chief Commercial Officer | ||
| Thomas BSc, Ex Officer | ||
| Patrick MA, CEO, CoFounder | ||
| Breanna Burkart, Sr. Director of Investor Relations | ||
| Patrick Mahaffy, President CEO, Director | ||
| Gillian IversRead, Executive Vice President - Technical Operations, Chief Regulatory Officer | ||
| Michael Barrett, Independent Chairman of the Board | ||
| James Blair, Independent Director | ||
| James Barrett, Independent Chairman of the Board | ||
| Richard Fair, Director | ||
| Edward McKinley, Independent Director | ||
| MB BSc, Chief Medical Officer and Executive VP of Clinical and Preclinical Devel. and Pharmacovigilance | ||
| Keith Flaherty, Director | ||
| Lindsey Rolfe, Chief Medical Officer, Executive Vice President - Clinical and Preclinical Development & Pharmacovigilance | ||
| Steven Hoerter, Chief Commercial Officer and Executive VP | ||
| Erle Mast, Co-Founder, CFO, Executive VP and Secretary | ||
| Ginger Graham, Independent Director | ||
| Ann Bozeman, Executive Vice President of Human Resources | ||
| Daniel Muehl, Principal Financial Officer, Principal Accounting Officer |
Clovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clovis Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Clovis Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Clovis Oncology's short interest history, or implied volatility extrapolated from Clovis Oncology options trading.
Pair Trading with Clovis Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clovis Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clovis Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Clovis Stock
| 0.78 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.77 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
| 0.65 | GE | GE Aerospace Financial Report 23rd of July 2024 | PairCorr |
| 0.64 | CAT | Caterpillar Earnings Call Today | PairCorr |
| 0.63 | CVX | Chevron Corp Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Clovis Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clovis Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clovis Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clovis Oncology to buy it.
The correlation of Clovis Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clovis Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clovis Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clovis Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |